Neuroimmunology Research

ENROLLING STUDIES:

The MS Leadership and Innovation Network (MS-LINK™) Outcomes Study: A Comprehensive Prospective Longitudinal Assessment of Patient and Clinical Reported Outcomes in Multiple Sclerosis Patients across North America
https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200077_0021

https://clinicaltrials.gov/ct2/show/NCT04735406?term=MS+Link&cond=Multiple+Sclerosis&draw=2&rank=1

Next Generation Learning Health System for Multiple Sclerosis (Next-Gen MS): A prospective, cluster-randomized study evaluating the impact of “feed-forward” patient reported outcomes data to clinical teams managing adults living with MS in a learning health system for MS research
https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200077_0013

https://clinicaltrials.gov/ct2/show/NCT04907305?term=MS+Link&cond=Multiple+Sclerosis&draw=2&rank=2

A Randomized double blind placebo controlled multicenter Phase 3 pivotal study to evaluate the efficacy and safety of rozanolixizumab to tx adults with Myelin Oligodendrovyte Glycoprotein (MOG) antibody associated disease (MOG001)
https://www.clincosm.com/trial/myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mog

https://clinicaltrials.gov/ct2/show/NCT05063162?term=MOG001&recrs=ad&cond=MOG&draw=2&rank=1

A randomized, double-blind, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib (REMODEL-2)

https://clinicaltrials.gov/ct2/show/NCT05156281?term=remibrutinib&draw=2&rank=3

COMPLETED STUDIES:

A Multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of AUBAGIO® Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

A Longitudinal Study To Identify and Validate Biomarkers From Serum and Cerebrospinal Fluid In Patients Evaluated By Neurologists

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

An Observational Study of Ocrelizumab-treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies